Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 10/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818662 | 1.00 | PTPN1 (0.47) | PTPN1BCHECNR2ITGB3ITGA2B | |
| SCHEMBL3865769 | 0.96 | SCN9A (0.44) | PTPN1BCHECNR2ITGB3ITGA2B | |
| SCHEMBL3864623 | 0.94 | SCN9A (0.44) | PTPN1BCHECNR2ITGB3ITGA2B | |
| SCHEMBL3862129 | 0.90 | PRMT5 (0.42) | PTPN1BCHECNR2ITGB3ITGA2B | |
| SCHEMBL3867006 | 0.88 | BCHE (0.44) | PTPN1BCHECNR2SCN9ASUCNR1 | |
| SCHEMBL4824736 | 0.88 | FNTA (0.45) | PTPN1SCN9AC3AR1FNTAFNTB | |
| SCHEMBL4824726 | 0.88 | FNTA (0.45) | PTPN1SCN9AC3AR1FNTAFNTB | |
| SCHEMBL4824730 | 0.88 | FNTA (0.45) | PTPN1SCN9AC3AR1FNTAFNTB | |
| SCHEMBL4816799 | 0.86 | C3AR1 (0.51) | PTPN1C3AR1FNTAFNTBCTSS | |
| SCHEMBL4816786 | 0.86 | C3AR1 (0.51) | PTPN1C3AR1FNTAFNTBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | claimed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20040266789-A1 | Substituted amino carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266789-A1 | Substituted amino carboxylic acids | PTPRS, PPM1B, PTPRO | PTPN1 16/4885BCHE 575/4885CNR2 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.